Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients-Reference-Cited by-同舟云学术

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Published:2020-04-01 Issue:5 Volume:34 Page:707-718
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Orkin Chloe,Eron Joseph J.,Rockstroh Jürgen,Podzamczer Daniel,Esser Stefan,Vandekerckhove Linos,Van Landuyt Erika,Lathouwers Erkki,Hufkens Veerle,Jezorwski John,Opsomer Magda

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference32 articles.

1. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial;Orkin;HIV Med,2013

2. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients;Cahn;AIDS,2011

3. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naive, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE);Flynn;Pediatr Infect Dis J,2014

4. HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies;Lathouwers;HIV Clin Trials,2017

5. A week 48 randomized phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients;Eron;AIDS,2018

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study;Antiviral Therapy;2024-04

2. Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure;Drug Design, Development and Therapy;2024-04

3. Predictors of Post-switch Viremia in People With HIV on Injectable Cabotegravir/Rilpivirine;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-01-01

4. A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults;Expert Review of Anti-infective Therapy;2023-10-10

5. Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection;Expert Review of Clinical Pharmacology;2023-09-07